Evaxion Biotech analyst ratings
Evaxion Biotech analyst ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/18/2022 | 545.16% | Oppenheimer | → $16 | Assumes | → Outperform |
| 03/02/2021 | 625.81% | Oppenheimer | → $18 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 07/18/2022 | 545.16% | 奧本海默 | → 16 美元 | 假設 | → 跑贏大盤 |
| 2021 年 2 月 3 日 | 625.81% | 奧本海默 | → 18 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
Evaxion Biotech Questions & Answers
Evaxion 生物技術問題與解答
The latest price target for Evaxion Biotech (NASDAQ: EVAX) was reported by Oppenheimer on July 18, 2022. The analyst firm set a price target for $16.00 expecting EVAX to rise to within 12 months (a possible 545.16% upside). 1 analyst firms have reported ratings in the last year.
奧本海默於2022年7月18日公佈了Evaxion Biotech（納斯達克股票代碼：EVAX）的最新目標股價。該分析公司將目標股價定爲16.00美元，預計EVAX將在12個月內升至12個月內（可能上漲545.16％）。1家分析公司去年公佈了評級。
The latest analyst rating for Evaxion Biotech (NASDAQ: EVAX) was provided by Oppenheimer, and Evaxion Biotech their outperform rating.
奧本海默對Evaxion Biotech（納斯達克股票代碼：EVAX）的最新分析師評級由奧本海默提供，而Evaxion Biotech則提供了跑贏大盤的評級。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Evaxion Biotech, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Evaxion Biotech was filed on July 18, 2022 so you should expect the next rating to be made available sometime around July 18, 2023.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Evaxion Biotech的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。Evaxion Biotech的最新評級是在2022年7月18日發佈的，因此您應該預計下一個評級將在2023年7月18日左右公佈。
While ratings are subjective and will change, the latest Evaxion Biotech (EVAX) rating was a with a price target of $0.00 to $16.00. The current price Evaxion Biotech (EVAX) is trading at is $2.48, which is within the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的Evaxion Biotech（EVAX）評級爲A，目標股價爲0.00美元至16.00美元。Evaxion Biotech（EVAX）目前的交易價格爲2.48美元，在分析師的預測區間內。